Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...

VanLanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...

The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Beyond BPD, vafidemstat is being evaluated in a Phase IIb trial for the treatment of negative symptoms in schizophrenia (EVOLUTION trial) and is part of Oryzon’s broader CNS precision medicine ...

Q4 2024 Earnings Call Transcript February 28, 2025 Longeveron Inc. beats earnings expectations. Reported EPS is $1.16, ...

The Phase Ib and Phase IIa studies showed a good safety and tolerability ... effect compared with current treatment options. A Phase IIb study, completed in 2023, showed that mesdopetam has ...

The Phase Ib and Phase IIa studies showed a good safety and tolerability ... effect compared with current treatment options. A Phase IIb study, completed in 2023, showed that mesdopetam has ...

Results from Alzamend's completed Phase IIA multiple-ascending dose study of AL001 in Alzheimer's patients and healthy subjects identified a maximum tolerated dose ("MTD”), as assessed by an ...